Methods for identifying and treating cancers that are homologous recombination (HR)-repair defective. In some aspects, HR defective cancers are treated with a PARP inhibitor therapy. Methods for sensitizing cancers to a PARP inhibitor therapy are also provided.

The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2,3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2,3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs. ##STR00001##

The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2,3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2,3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs. ##STR00001##

The present invention is directed to a palatable soft chew veterinary composition comprising at least one active agent, at least one binding agent, at least one disintegrant, at least one wetting agent, and at least one flavorant, and methods for controlling or treating a condition in an animal comprising administering the composition to said animal in need thereof.

The present invention is directed to a palatable soft chew veterinary composition comprising at least one active agent, at least one binding agent, at least one disintegrant, at least one wetting agent, and at least one flavorant, and methods for controlling or treating a condition in an animal comprising administering the composition to said animal in need thereof.

The present invention is directed to a palatable soft chew veterinary composition comprising at least one active agent, at least one binding agent, at least one disintegrant, at least one wetting agent, and at least one flavorant, and methods for controlling or treating a condition in an animal comprising administering the composition to said animal in need thereof.

The present invention provides, inter alia, compositions, methods, and diagnostics for using CB2 cannabinoid receptor agonists for treating and preventing lysosomal storage disorders.

A compound represented by the general formula (I) [R.sup.1 represents a C.sub.1-6 alkyl group, a halogen atom, or the like; A represents a phenylene group, or the like; X represents —CH(R.sup.3)—, —O—, —NH—, or the like; Y represents —O—, —NH—, —N═, or —S—; . . . represents a single bond or double bond; n represents 1 to 3; R.sup.2 represents a C.sub.1-6 alkyl group, a C.sub.1-6 alkoxy group, or the like; and R.sup.3 represents hydrogen atom, a C.sub.1-6 alkyl group, or the like], or a salt thereof which has a blood LDL cholesterol-reducing action, and is useful as an active ingredient of medicaments.

##STR00001##

The present invention relates to ##STR00001##
or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.

The present invention relates to ##STR00001##
or a pharmaceutically acceptable salt or ester prodrug thereof for use in the treatment of a mycobacterial infection or disease resulting from a mycobacterial infection, such as tuberculosis.